# US 2026/0076951 A1 · Methods of treating fabry disease in patients having renal impairment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0076951 A1
- Document ID: US20260076951A1
- Status: Published application
- Kind: A1
- Application number: 19/333,835
- Filed: 2025-09-19
- Published: 2026-03-19
- Earliest claimed: 2024-09-19
- Assignees: Amicus Therapeutics, Inc.
- Applicants: Amicus Therapeutics, Inc.
- Inventors: Franklin Johnson
- Web page: https://patentgrep.com/patent/US20260076951A1

## CPC

- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61P 13/12: of the kidneys
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are methods of treating Fabry disease in a patient having severe renal impairment. A method for the treatment of Fabry disease in a patient having severe renal impairment, including administering to the patient about 50 mg to about 200 mg free base equivalent (FBE) of migalastat or salt thereof at a frequency of less than once every week. A method for the treatment of Fabry disease in a patient having severe renal impairment, including administering to the patient about 50 mg to about 100 mg free base equivalent of migalastat or salt thereof at a frequency of between about once every three days and about once every two weeks.

## Claims

### Claim 1

A method for the treatment of Fabry disease in a patient having severe renal impairment, the method comprising administering to the patient about 50 mg to about 200 mg free base equivalent (FBE) of migalastat or salt thereof at a frequency of less than once every week.

### Claim 2 (depends on 1)

The method of claim 1, wherein the frequency is about once every two weeks.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the patient is administered about 150 mg of migalastat HCl.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the patient is administered about 123 mg free base equivalent (FBE) of migalastat.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the severe renal impairment is end stage renal disease (ESRD).

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the patient has an estimated glomerular filtration rate (eGFR) of less than about 30 mL/min/1.73 m2.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the patient has an estimated glomerular filtration rate (eGFR) of less than about 15 ml/min/1.73 m2.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the patient is undergoing a dialysis treatment.

### Claim 9 (depends on 8)

The method of claim 8, wherein the dialysis treatment comprises hemodialysis or hemodiafiltration.

### Claim 10 (depends on 8, 9)

The method of claim 8 or 9, wherein the migalastat is administered between about 12 hours and about 36 hours prior to the dialysis treatment.

### Claim 11 (depends on 10)

The method of claim 10, wherein the migalastat is administered about 24 hours prior to the dialysis treatment.

### Claim 12 (depends on 8, 9, 10, 11)

The method of any one of claims 8-11, wherein the dialysis treatment is performed twice per week or three times per week.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1-12, wherein the patient has a HEK assay amenable mutation in α-galactosidase A.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, wherein the migalastat is in a solid dosage form.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 1-14, wherein the migalastat is administered orally.

### Claim 16

A method for the treatment of Fabry disease in a patient having severe renal impairment, the method comprising administering to the patient about 50 mg to about 100 mg free base equivalent (FBE) of migalastat or salt thereof at a frequency of between about once every three days and about once every two weeks.

### Claim 17 (depends on 16)

The method of claim 16, wherein the frequency is about once every seven days.

### Claim 18 (depends on 16, 17)

The method of claim 16 or 17, wherein the patient is administered about 100 mg of migalastat HCl.

### Claim 19 (depends on 16, 17, 18)

The method of any one of claims 16-18, wherein the patient is administered about 82 mg free base equivalent (FBE) of migalastat.

### Claim 20 (depends on 16, 17, 18, 19)

The method of any one of claims 16-19, wherein the severe renal impairment is end stage renal disease (ESRD).

### Claim 21 (depends on 16, 17, 18, 19, 20)

The method of any one of claims 16-20, wherein the patient has an estimated glomerular filtration rate (eGFR) of less than about 30 mL/min/1.73 m2.

### Claim 22 (depends on 16, 17, 18, 19, 20, 21)

The method of any one of claims 16-21, wherein the patient has an estimated glomerular filtration rate (eGFR) of less than about 15 mL/min/1.73 m2.

### Claim 23 (depends on 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 16-22, wherein the patient is undergoing a dialysis treatment.

### Claim 24 (depends on 23)

The method of claim 23, wherein the dialysis treatment comprises hemodialysis or hemodiafiltration.

### Claim 25 (depends on 23, 24)

The method of claim 23 or 24, wherein the migalastat is administered between about 12 hours and about 36 hours prior to the dialysis treatment.

### Claim 26 (depends on 25)

The method of claim 25, wherein the migalastat is administered about 24 hours prior to the dialysis treatment.

### Claim 27 (depends on 23, 24, 25, 26)

The method of any one of claims 23-26, wherein the dialysis treatment is performed twice per week or three times per week.

### Claim 28 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 16-27, wherein the patient has a HEK assay amenable mutation in α-galactosidase A.

### Claim 29 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 16-28, wherein the migalastat is in a solid dosage form.

### Claim 30 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 16-29, wherein the migalastat is administered orally.

### Claim 31

Use of migalastat in the treatment of Fabry disease in a patient having severe renal impairment, the use of migalastat comprising administering to the patient about 50 mg to about 300 mg free base equivalent (FBE) of migalastat or salt thereof at a frequency of less than once every week.

### Claim 32

Use of migalastat in the treatment of Fabry disease in a patient having severe renal impairment, the use of migalastat comprising administering to the patient about 50 mg to about 100 mg free base equivalent (FBE) of migalastat or salt thereof at a frequency of between about once every three days and about once every two weeks.
